SEC Comment Letter for IN8BIO, (INAB) — Jan 27, 2026
IN8BIO, INC.
Date: Jan. 27, 2026 · CIK: 0001740279 · Accession: 0000000000-26-000935
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292830
Letter
Re: IN8bio, Inc. Registration Statement on Form S-3 Filed January 20, 2026 File No. 333-292830 Dear William Ho:
January 23, 2026
William Ho President and Chief Executive Officer IN8bio, Inc. 350 5th Avenue, Suite 5330 New York, NY 10118
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jaime L. Chase, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> January 23, 2026 William Ho President and Chief Executive Officer IN8bio, Inc. 350 5th Avenue, Suite 5330 New York, NY 10118 Re: IN8bio, Inc. Registration Statement on Form S-3 Filed January 20, 2026 File No. 333-292830 Dear William Ho: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jaime L. Chase, Esq. </TEXT> </DOCUMENT>